Loading...
Home
Home2018-10-23T18:21:54+00:00

Applying methylation haplotype analysis to cell-free DNA

DNA methylation has once been called the '5th DNA base' due to its importance in gene regulation, and has been studied for decades. With the advent of next-generation sequencing (NGS) methylation has been studied on a genome-wide level, an expensive process requiring both generating sequence data and analyzing sequence data many orders of magnitude higher than what a typical clinical laboratory can handle.

Targeted methylation approaches have historically not been developed due to technical hurdles. Singlera announces a unique approach, examining methylation haplotypes (adjacent methylation sites on the same contiguous strand of DNA) from cell-free DNA as a method for cancer biomarker detection.

By using a highly specific and targeted methylation enrichment method, both the overall sample input requirement is lowered and the overall amount of sequencing necessary for excellent sensitivity is reduced.

  • Empirical Classifier – Derived from over 20,000 methylation haplotypes and 10 years of volunteer samples

  • High Sensitivity and Specificity – Analytical results show greater than 97% sensitivity and over 99% specificity *

  • Early Detection of Cancer – Data suggests detection of cancer four years before earliest conventional diagnosis

* The ColonES assay sensitivity for CRC Stage I in clinical samples

Efficient biomarker screening technology coupled with fast custom targeted methylation haplotyping and proprietary bioinformatics analysis.

Research

Take a closer look at our leading-edge research in methylation and its role in disease in top research publications.

Method

Learn how Singlera’s methylation haplotyping technology can give better cancer biomarker sensitivity.

Available Assays

Learn more about our two assays, PanSeer to detect several cancer types, and ColonES that specifically detects colorectal cancer markers with high sensitivity and specificity.

Collaboration and Co-Development

Do you see promise in our methylation haplotype approach? Do you think it could complement work you are doing in developing in-vitro diagnostics for cancer?

62%

Sensitivity of PanSeer 4 years pre-conventional diagnosis

92%

Specificity of PanSeer across 498 healthy individuals

97%

Sensitivity of ColonES in Stage I Colorectal cancer

99%

Specificity of ColonES in healthy individuals

 

0
Taizhou China volunteers
0
Years volunteers monitored
0
Number of methylation haplotype markers used in ColonES
0
Hours from DNA to sequencer-ready library

 

The Co-Founders of Singlera Genomics

Yuan Gao, CEO and Co-Founder of Singlera Genomics
Dr. Yuan Gao Ph.D., Chairman and Co-Founder
Dr. Kun Zhang Co-Founder Singlera Genomics
Kun Zhang, Ph.D., Co-founder and Scientific Advisor
Johny Zhang MBA
Johny Zhang, M.B.A., Co-Founder, Chief Executive Officer
Dr. Rui Liu CTO Singlera Genomics
Rui Liu, Ph.D., Co-Founder, Chief Technology Officer
Qiang Liu MBA
Qiang Liu, M.B.A., Co-Founder, Chief Operating Officer

Discover The Future

At the leading edge of biology and assay technology, Singlera Genomics uses a new biomarker type called ctmDNA (circulating tumor methylated DNA) to peer into the future.

Contact Us
Email Signup
Good things come to those who sign up for
An Early Mark
Join our email list to get the latest blog posts straight to your inbox
SUBSCRIBE
Give it a try, you can unsubscribe anytime.
close-link